Al­ler­gan set to make head­way in crowd­ed CGRP mi­graine mar­ket, as the bat­tle for for­mu­la­ry cov­er­age be­gins

Mil­lions of mi­graine suf­fer­ers could soon get their hands on an oral CGRP drug de­signed to be used as-need­ed, as Al­ler­gan $AGN on Wednes­day said it was on track to file for FDA ap­proval for ubro­gepant in the first quar­ter of next year. The mul­ti-bil­lion dol­lar mi­graine mar­ket is al­ready re­plete with in­jectable med­ica­tions from Te­va $TE­VA, Eli Lil­ly $LLY, and one from Am­gen $AMGN and No­var­tis $NVS, which are all de­signed to be used as pre­ven­ta­tive treat­ments and are cu­ri­ous­ly priced iden­ti­cal­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.